PMID- 34691029
OWN - NLM
STAT- MEDLINE
DCOM- 20220107
LR  - 20231102
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in 
      Colorectal Cancer.
PG  - 724883
LID - 10.3389/fimmu.2021.724883 [doi]
LID - 724883
AB  - Colorectal cancer (CRC) is the third most diagnosed malignancy and the second 
      leading cause of cancer-related deaths worldwide. Locally advanced and metastatic 
      disease exhibit resistance to therapy and are prone to recurrence. Despite 
      significant advances in standard of care and targeted (immuno)therapies, the 
      treatment effects in metastatic CRC patients have been modest. Untreatable cancer 
      metastasis accounts for poor prognosis and most CRC deaths. The generation of a 
      strong immunosuppressive tumor microenvironment (TME) by CRC constitutes a major 
      hurdle for tumor clearance by the immune system. Dendritic cells (DCs), often 
      impaired in the TME, play a critical role in the initiation and amplification of 
      anti-tumor immune responses. Evidence suggests that tumor-mediated DC dysfunction 
      is decisive for tumor growth and metastasis initiation, as well as for the 
      success of immunotherapies. Unravelling and understanding the complex crosstalk 
      between CRC and DCs holds promise for identifying key mechanisms involved in 
      tumor progression and spread that can be exploited for therapy. The main goal of 
      this review is to provide an overview of the current knowledge on the impact of 
      CRC-driven immunosuppression on DCs phenotype and functionality, and its 
      significance for disease progression, patient prognosis, and treatment response. 
      Moreover, present knowledge gaps will be highlighted as promising opportunities 
      to further understand and therapeutically target DC dysfunction in CRC. Given the 
      complexity and heterogeneity of CRC, future research will benefit from the use of 
      patient-derived material and the development of in vitro organoid-based 
      co-culture systems to model and study DCs within the CRC TME.
CI  - Copyright (c) 2021 Subtil, Cambi, Tauriello and de Vries.
FAU - Subtil, Beatriz
AU  - Subtil B
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Cambi, Alessandra
AU  - Cambi A
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - Tauriello, Daniele V F
AU  - Tauriello DVF
AD  - Department of Cell Biology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
FAU - de Vries, I Jolanda M
AU  - de Vries IJM
AD  - Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, 
      Radboud University Medical Center, Nijmegen, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20211006
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Colorectal Neoplasms/*immunology/pathology
MH  - Dendritic Cells/*immunology/pathology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Organ Culture Techniques
MH  - Tumor Microenvironment/drug effects/*immunology
PMC - PMC8527179
OTO - NOTNLM
OT  - cancer immunity
OT  - dendritic cell defects
OT  - immunosuppression
OT  - immunotherapy
OT  - metastatic colorectal cancer
OT  - patient-derived organoids
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/26 06:00
MHDA- 2022/01/08 06:00
PMCR- 2021/01/01
CRDT- 2021/10/25 06:25
PHST- 2021/06/14 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/10/25 06:25 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2022/01/08 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.724883 [doi]
PST - epublish
SO  - Front Immunol. 2021 Oct 6;12:724883. doi: 10.3389/fimmu.2021.724883. eCollection 
      2021.